| Title | Thermosensitive Hydrogel Containing Doxycycline Exerts Inhibitory Effects on Abdominal Aortic Aneurysm Induced By Pancreatic Elastase in Mice |
| Authors | Yu, Maomao Dong, Anjie Chen, Cong Xu, Shuxin Cao, Yini Liu, Shu Zhang, Qiang Qi, Rong |
| Affiliation | Peking Univ, Inst Cardiovasc Sci,Hlth Sci Ctr, Key Lab Mol Cardiovasc Sci,Minist Educ, Beijing Key Lab Mol Pharmaceut & New Drug Deliver, 38 Xueyuan Rd, Beijing 100191, Peoples R China. Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China. Shihezi Univ, Coll Pharm, Key Lab Xinjiang Endem Phytomed Resources, Minist Educ, Xinjiang 832003, Peoples R China. Peking Univ, Sch Pharmaceut Sci, Beijing Key Lab Mol Pharmaceut & New Drug Deliver, 38 Xueyuan Rd, Beijing 100191, Peoples R China. |
| Keywords | abdominal aortic aneurysm doxycycline PECT thermosensitive hydrogels SUSTAINED-RELEASE HYALURONIC-ACID DRUG-DELIVERY DEGRADATION PACLITAXEL COPOLYMERS EFFICIENCY MODEL |
| Issue Date | 2017 |
| Publisher | ADVANCED HEALTHCARE MATERIALS |
| Citation | ADVANCED HEALTHCARE MATERIALS. 2017, 6(22). |
| Abstract | Doxycycline (DOX) is reported to exert therapeutic effects against abdominal aortic aneurysm (AAA), a severe degenerative disease. In this study, a DOX hydrogel formulation of DOX/PECTgel is studied, and its phase transition behavior and in vitro release profiles are explored. In addition, the anti-AAA effects and bioavailability of DOX/PECTgel are evaluated in an elastase induced AAA mouse model. The results show that the phase transition temperature of 30% poly(e-caprolactone-co-1,4,8-trioxa[4.6] spiro-9-undecanone) (PECT) solution is above 34 degrees C. In vitro release profiles of DOX/PECTgel indicate a fast release of DOX at the first two days, followed by a slow and sustained release for 14 d. In vivo single-dose single subcutaneous injection of DOX/PECTgel containing 8.4 or 4.2 mg mL(-1) DOX presents comparatively preventive effects on AAA, compared to intraperitoneal injections of DOX alone at a dose of 15 mg kg(-1) for seven injections, while DOX bioavailability of the DOX/PECTgel treated groups is 1.39 times or 1.19 times of the DOX alone treated group, respectively. |
| URI | http://hdl.handle.net/20.500.11897/500802 |
| ISSN | 2192-2640 |
| DOI | 10.1002/adhm.201700671 |
| Indexed | SCI(E) PubMed Medline |
| Appears in Collections: | 基础医学院 药学院 |
